Sunfox Technologies, an Indian medtech firm developing portable cardiac diagnostic devices, has raised $7 million in a Series A round to scale its flagship Spandan platform, targeting expanded deployment domestically and regulatory footholds abroad.
- Raised $7M led by Ashish Kacholia, Alchemy Capital, and others
- Plans to expand Spandan devices across India and global markets
- Supports R&D, regulatory approvals, and commercial infrastructure
What happened
Sunfox Technologies, a medtech startup based in Dehradun, India, announced the completion of a $7 million Series A funding round. The investment was led by prominent investors including Ashish Kacholia, Lashit Sanghvi, Alchemy Capital, and 3one4 Capital. This fresh capital injection follows a prior $1.8 million round in 2024 led by Venture Catalysts.
The startup plans to deploy the new funding to scale its portable cardiac diagnostic platform, Spandan, within India and develop regulatory, distribution, and commercial capabilities for the US, European, and African markets. Sunfox also intends to enhance research and development, clinical validation, and the engineering of new cardiac technologies.
Why it matters
Sunfox’s Spandan platform offers portable AI-enabled ECG devices integrated with smartphone technology, enabling easy cardiac monitoring in clinical and public health settings. Its solutions cater to hospitals, clinics, telemedicine networks, and remote healthcare through digital platforms like Spandan One, which facilitates tele-ECG network management and remote patient monitoring.
What to watch next
Investors and industry observers will be closely monitoring Sunfox’s progress in obtaining regulatory clearances in the US and EU markets, which are crucial for its international expansion plans. The ability to establish a robust commercial presence outside India will be key to its long-term growth trajectory.
Meanwhile, the effectiveness and adoption of its AI-powered diagnostic tools within India’s vast public health and telemedicine ecosystems will also be critical. Success in scaling Spandan devices and digital services could position Sunfox as a major player in portable cardiac diagnostics regionally and globally, especially amid growing demand for remote patient monitoring.